Inclisiran Cuts LDL by 33% in Teens With Deadly Inherited Cholesterol Disorder

Homozygous familial hypercholesterolemia (HoFH) is a rare but life-threatening inherited disorder causing severely elevated LDL cholesterol from birth and accelerated atherosclerotic cardiovascular disease in childhood and young adulthood. Estimated to affect roughly 1 in 300,000 people worldwide, HoFH frequently goes undertreated in pediatric populations, and most patients never reach guideline-recommended LDL-C targets despite multiple lipid-lowering therapies. New treatment options for young patients are urgently needed.

ORION-13 is a phase 3, two-part multicenter trial conducted across 9 centers in 8 countries specifically designed to fill this gap. The double-blind, placebo-controlled first year of the study enrolled 13 adolescents (ages 12 to <18) with genetically confirmed HoFH, excluding those with the most severe LDLR null/null genotype given their near-zero residual LDL receptor activity. All patients had LDL-C above 130 mg/dL despite maximally tolerated statin therapy. They were randomized 2:1 to receive subcutaneous injections of inclisiran sodium 300 mg or placebo on days 1, 90, and 270. Mean baseline LDL-C was a very high 272 mg/dL.

The primary endpoint—placebo-adjusted mean percentage change in LDL-C from baseline to day 330—was −33.3% (95% CI: −59.2% to −7.3%). Six of 9 inclisiran-treated patients (66.7%) achieved greater than 15% LDL-C reduction versus 1 of 4 placebo patients (25%), and 5 of 9 (55.6%) achieved greater than 20% reduction versus none on placebo. PCSK9 levels fell by a placebo-adjusted 60.2%, confirming target engagement. Meaningful reductions were also seen in apolipoprotein B (−23.0%), non-HDL cholesterol (−32.7%), and total cholesterol (−27.8%). Responses were heterogeneous and correlated with genotype: patients with at least some residual LDLR activity responded better than those approaching null status.

Safety findings were reassuring across the board. No serious adverse events, treatment discontinuations due to adverse events, or deaths occurred. Injection-site reactions were mild and transient. Critically for a pediatric population, growth parameters, pubertal development assessed by Tanner staging, and hormonal levels (including LH, FSH, cortisol, estradiol/testosterone) showed no drug-related concerns. No anti-drug antibodies were detected.

The study's main limitations are its very small sample size (n=13), driven by the rarity of the disease, and the absence of formal statistical power calculations. Inclisiran's mechanism—upregulating LDLR—means it requires at least some residual LDLR activity to work, limiting applicability to the most severe null/null genotype patients. Longer-term follow-up from part 2 (the open-label extension) will be important to confirm durability and sustained safety. Nonetheless, these results are consistent with inclisiran's established efficacy profile in adults and provide meaningful early evidence supporting its use in adolescents with HoFH who retain minimum LDLR residual activity.